Abstract 4144008: MindMoves: Effect of Lifestyle Physical Activity and Cognitive Training Interventions on Blood Biomarkers in Older Women with Cardiovascular Disease

Circulation, Volume 150, Issue Suppl_1, Page A4144008-A4144008, November 12, 2024. Background:Physical activity and cognitive training can improve cognitive health, including related neurotrophic biomarkers, with potential interactive effects. In older women with cardiovascular disease (CVD) who are at increased risk for poor cognitive health, we evaluated the efficacy ofMindMoves, a 24-week multidomain physical activity and cognitive training intervention, on change in serum biomarkers, including brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), and growth differentiation factor 15 (GDF-15).Methods:This randomized controlled trial (NCT04556305) with a 2×2 factorial design tested independent and combined efficacies ofMind(tablet-based cognitive training) andMove(lifestyle physical activity) on change in serum biomarkers (BDNF, VEGF, IGF-1, GDF-15). Women (n= 253) aged 65 years and older with CVD were randomized toMind,Move,MindMoves, or usual care. Women completed fasting venipunctures at baseline, 24, 48, and 72 weeks. We conducted multilevel linear growth models adjusting for age, education, and racial and ethnic background. To examine intervention effects on linear change in serum biomarkers over 72 weeks, we included main and interaction effects ofMindandMove.Results:Participants were, on average, 72.4 years old at baseline (range= 65–90), primarily of non-Hispanic White (54%) and Black (38%) racial backgrounds, and 60% graduated college. A total of 86% (n= 218) of participants completed the 72-week data collection. Attrition was not a significant function of intervention condition or sociodemographics (allp’s > .05). There were no significant main effects ofMindorMoveon linear change for any of the four serum biomarkers. However, there was a significant interaction effect (Mind*Move) on linear change over all four timepoints for GDF-15, whereby those in the control and combined conditions improved (decreased) relative to those in theMindorMoveconditions (t= -2.20,p= .028).Conclusions:In this cohort of older women with CVD, there were significantMind*Moveinteractive effects on GDF-15, a biomarker that may be associated with risk of Alzheimer’s disease or other conditions related to neuroinflammation. However, there were no significant intervention effects for the other biomarkers. Future analyses should examine other biomarkers related to Alzheimer’s disease and inflammation that may provide more mechanistic insight.

Read More

Abstract 4136600: Hypertensive disorders of pregnancy and the risk of Dementia, Alzheimer’s disease, and Vascular Dementia. A Systematic review and Meta-analysis of 25,03,538 women participants.

Circulation, Volume 150, Issue Suppl_1, Page A4136600-A4136600, November 12, 2024. Background:Hypertensive disorders of pregnancy (HDP) are associated with maternal adverse cardiovascular outcomes. However, their association with maternal Dementia and Alzheimer’s disease is not well established with limited and conflicting results to date.Objective:We sought to evaluate the association between HDP and risk of incidence of Dementia, and Alzheimer’s disease.Methods:We performed a systematic review and meta-analysis of available literature that enrolled women with HDP and women without HDP groups. PubMed, Embase and ClinicalTrials.gov were systematically searched from inspection till May 2024 without any language restrictions. Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) were pooled using a random-effect model.Results:A total of 8 studies with 2503538 patients (1,51,905 in women with HDP and 23,51,633 in the women without HDP group) were included. Pooled analysis shows that HDP women were having 37% higher risk of dementia (aHR, 1.37(95%CI: 1.27-1.46), P

Read More

Abstract 4119913: Aging-Associate Peptide Medin Induces Proinflammatory Activation in Human Brain Vascular Smooth Muscle Cells

Circulation, Volume 150, Issue Suppl_1, Page A4119913-A4119913, November 12, 2024. Background:Medin is one of the most common amyloidogenic proteins and accumulates in the vasculature with aging. Vascular medin accumulation is associated with Alzheimer’s disease, vascular dementia and aortic aneurysms.In vitro, medin has been shown to induce endothelial proinflammatory activation and inex vivohuman cerebral arterial tissue, medin induces both endothelial and smooth muscle dysfunction. The role of medin in vascular smooth muscle (VSMC) activation remains unknown.Aim:The aim of the study is to determine using gene transcription assay whether medin induces VSMC activation and phenotypic transformation.Methods:Human brain vascular smooth muscle cells (HBVSMCs, passages 6-10) were exposed to medin at doses observed in human tissues (0, 0.5, 1 and 5 υM) for 20 hours and reverse transcription polymerase chain reaction (rtPCR) was used to quantify gene expression of proinflammatory factors (interleukin (IL)-6, IL-8, IL-1b) and structural and enzyme proteins associated with VSMC phenotypic transformation (ACTA2, MYH11 and NOX4). In separate experiments, HBVSMCs were exposed to vehicle, medin 5 υM without or with small molecule NFκB inhibitor RO106-9920 (10 υM) or NLGM1 nanoliposome (70% phosphatidylcholine, 25% cholesterol, 5% monosialoganglioside, 100 υg/mL, agent shown to reverse medin-induced endothelial dysfunction and proinflammatory activation).Results:Medin induced a dose-dependent increase in gene expression of IL-6, IL-8 and IL-1b but did not alter gene expression of ACTA2, MYH11 and NOX4 (Fig. 1). Co-treatment of medin with RO106-9920 and NLGM1 showed a trend (not statistically significant) of reduced IL-6 and IL-8 (Fig. 2).Conclusions:Physiologic doses of medin induced pro-inflammatory activation of HBVSMCs but did not affect gene expression of structural proteins (ACTA2 and MYH11) and enzyme (NOX4) involved in VSMC phenotypic transformation. Although the mechanisms behind this effect remains to be explored, results suggest that medin may be an important mediator of aging-associated vascular inflammation.

Read More

Abstract 4146706: Amyloidogenic Medin Induces Prothrombotic Activation in Human Brain Microvascular Endothelial Cells

Circulation, Volume 150, Issue Suppl_1, Page A4146706-A4146706, November 12, 2024. Background:The endothelium plays a major role in preventing thrombosis. Aging leads to a hypercoagulable state with increased procoagulant factors without accompanying rise in anticoagulant factors, shifting the balance to a prothrombotic profile. This increases the risk for conditions such as stroke or myocardial infarction. The mediator/s of this change remains unknown. Medin is a 50 amino acid cleavage product of MFGE8, accumulates in the vasculature with aging and is the most common human amyloid. Vascular medin burden is increased in vascular dementia, Alzheimer’s disease and aortic aneurysms. Medin was shown to induce endothelial and smooth muscle dysfunction and endothelial pro-inflammatory activation. Its role in aging-associated prothrombotic activation is unknown.Aim:To determine the effect of medin on human brain microvascular endothelial cells (HBMVECs) expression and function of thrombomodulin (a transmembrane glycoprotein that is a major anticoagulant through its interaction with thrombin leading to activation of protein C and S which in turn degrades factors Va and VIIIa) and HBMVEC expression of plasminogen activator inhibitor-1 (PAI-1) and tissue factor (major procoagulant proteins).Methods:Primary HBMVECs (passages 6-8) were exposed for 20 hours to physiologic doses of recombinant human medin (1 or 5 uM) and gene and protein expression of thrombomodulin, PAI-1 and tissue factor were measured using rtPCR or Western blot, respectively. In separate experiments, assessment of thrombomodulin function was determined by exposing HBMVECs for 20 hours to medin, after which human protein C (0.2 uM) and α-thrombin (10 nM) were added for 1 hour and amount of activated protein C in media was measured using ELISA.Results:Physiologic dose of medin (5 uM) given to HBMVECs resulted in reduced gene and protein expression of thrombomodulin (Fig. 1), increased gene and protein expression of PAI-1 (Fig. 2), and modest increased protein, but not gene expression of tissue factor (Fig. 3). Medin exposure also reduced HBMVEC ability to convert protein C to activated protein C in the presence of thrombin.Conclusions:Medin reduced HBMVEC production of anticoagulant protein thrombomodulin and increased protein expression of procoagulant proteins PAI-1 and tissue factor. Medin is a potential novel mediator of aging-associated hypercoagulability and could be a promising target in thrombotic diseases such as stroke.

Read More

Abstract 4143721: Large Sample Size Magnetic Resonance Imaging Measurements to Assess the Relation between Cardiac Function and Structure and White Matter Hyperintensity Volumes.

Circulation, Volume 150, Issue Suppl_1, Page A4143721-A4143721, November 12, 2024. Background:People with established cardiovascular disease (CVD) are at risk of early cognitive decline, and neurodegenerative diseases such as dementia. White matter hyperintensities (WMH) of presumed vascular origin are associated with progressive cerebrovascular disease and risk factors for CVD. The shared risk factors include blood pressure, sedentary lifestyle, genomic risk factors likeAPOE4mutations. The extent to which common risk factors explain the co-occurrence of CVD and neurological diseases is unclear.Purpose:To determine the extent of which CMR measurements associated with WMH independent of known cerebrovascular risk factors.Methods:Cardiac and brain MRI images were analysed for 33,198 UK biobank participants. WMH analysis included 5 brain regions (Frontal, Parietal, Temporal, Occipital, Basal Ganglia and Thalami) and total brain WMH volume. Cardiac traits included stroke volumes, atrial volumes, ejection fractions (EF) of right and left chambers, left ventricular (LV) strain, LV wall thickness and aortic areas.Multivariable regression analysis was carried out, where each cardiac trait was regressed on each brain region and adjusted for demographics, cardiac risk factors, family history of disease and socioeconomic factors. Results were evaluated against a multiple testing correct p-value threshold of 0.05, reflecting the number of principle components(n=10) necessary to explain at least 90% of the cardiac trait variability.Results:Higher values of 7 cardiac traits (LV end stroke volume, aortic areas, mid and basal wall thickness) associated with higher WMH volumes for all brain regions. Conversely three traits (LV ejection fraction, descending aorta distensibility and RV ejection fraction) associated positively with lower WMH volumes for all brain regions. LV cardiac output and maximum LAV only associated with frontal lobe WMH volumes. Associations onAPOE- ε4 carriership, a known risk factor of Alzheimer’s disease, showed negative association in homozygous carriers between aortic distensibility of the ascending and descending aorta and higher WMH volumes in the frontal and occipital lobes.Conclusions:This study offers insight into WMH burden in a large population of adults. Using cardiac traits as surrogate markers of different cardiac disease could explain how cardiac functionality defines WMH volume distribution and subsequently the wider relationship between cardiovascular and cerebrovascular disease.

Read More